Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19
Status:
Recruiting
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
SINGLE CENTER PHASE III INTERVENTIONAL RANDOMIZED CONTROLLED TRIAL comparing efficacy and
safety of enoxaparin at prophylactic dose (standard treatment) and enoxaparin at therapeutic
dose (OFF-LABEL treatment) in 300 COVID-19 infected patients with moderate-severe respiratory
failure (PaO2/FiO2<250) and/or increased D-dimer levels enrolled in different Units
(Infectious disease, Internal Medicine, Emergency Medicine, Pneumology) of Azienda Socio
Sanitaria Territoriale Fatebenefratelli Sacco (ASST-FBF-SACCO).